Jag Shur is a pioneering researcher and entrepreneur. He is currently CTO at RIGImmune Inc, a clinical stage biotech developing advanced nucleic acid treatments for respiratory medicine.

Shur holds a Ph.D. in Inhaled Biopharmaceutics: Drug Delivery to the Cystic Fibrosis Airways from the University of Portsmouth and has led significant advancements in drug delivery systems throughout his career. Before completing his Ph.D., Shur was the leader of the advanced drug formulation design team at Profile Drug Delivery, where he spearheaded the development of innovative liquid-dose inhaler formulations. Subsequently, at GlaxoSmithKline, Shur excelled as the lead formulator and analytical scientist for dry powder inhalers and pressurized metered dose inhalers.

During a research fellowship at the University of Bath, Shur founded and served as CEO of Nanopharm Ltd, successfully guiding the company to an exit in June 2019. Following this, Shur founded Subintro Ltd, which was acquired by RIGimmune Inc in 2021, where he continues to develop groundbreaking inhaled RNA therapeutics.

Shur has published extensively in peer-reviewed journals and presented at international conferences, contributing significantly to the field of inhalation drug delivery. He is also a member of several professional organizations and advisory boards, reflecting his commitment to advancing scientific research and practical applications in medicine.

Throughout his career, Shur has demonstrated a unique ability to bridge the gap between complex scientific concepts and their practical applications, driving innovation and improving healthcare outcomes.